1
|
Greenwood TA, Lazzeroni LC, Maihofer AX, Swerdlow NR, Calkins ME, Freedman R, Green MF, Light GA, Nievergelt CM, Nuechterlein KH, Radant AD, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Gur RC, Gur RE, Braff DL. Genome-wide Association of Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia (COGS) Study. JAMA Psychiatry 2019; 76:1274-1284. [PMID: 31596458 PMCID: PMC6802253 DOI: 10.1001/jamapsychiatry.2019.2850] [Citation(s) in RCA: 64] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
IMPORTANCE The Consortium on the Genetics of Schizophrenia (COGS) uses quantitative neurophysiological and neurocognitive endophenotypes with demonstrated deficits in schizophrenia as a platform from which to explore the underlying neural circuitry and genetic architecture. Many of these endophenotypes are associated with poor functional outcome in schizophrenia. Some are also endorsed as potential treatment targets by the US Food and Drug Administration. OBJECTIVE To build on prior assessments of heritability, association, and linkage in the COGS phase 1 (COGS-1) families by reporting a genome-wide association study (GWAS) of 11 schizophrenia-related endophenotypes in the independent phase 2 (COGS-2) cohort of patients with schizophrenia and healthy comparison participants (HCPs). DESIGN, SETTING, AND PARTICIPANTS A total of 1789 patients with schizophrenia and HCPs of self-reported European or Latino ancestry were recruited through a collaborative effort across the COGS sites and genotyped using the PsychChip. Standard quality control filters were applied, and more than 6.2 million variants with a genotyping call rate of greater than 0.99 were available after imputation. Association was performed for data sets stratified by diagnosis and ancestry using linear regression and adjusting for age, sex, and 5 principal components, with results combined through weighted meta-analysis. Data for COGS-1 were collected from January 6, 2003, to August 6, 2008; data for COGS-2, from June 30, 2010, to February 14, 2014. Data were analyzed from October 28, 2016, to May 4, 2018. MAIN OUTCOMES AND MEASURES A genome-wide association study was performed to evaluate association for 11 neurophysiological and neurocognitive endophenotypes targeting key domains of schizophrenia related to inhibition, attention, vigilance, learning, working memory, executive function, episodic memory, and social cognition. RESULTS The final sample of 1533 participants included 861 male participants (56.2%), and the mean (SD) age was 41.8 (13.6) years. In total, 7 genome-wide significant regions (P < 5 × 10-8) and 2 nearly significant regions (P < 9 × 10-8) containing several genes of interest, including NRG3 and HCN1, were identified for 7 endophenotypes. For each of the 11 endophenotypes, enrichment analyses performed at the level of P < 10-4 compared favorably with previous association results in the COGS-1 families and showed extensive overlap with regions identified for schizophrenia diagnosis. CONCLUSIONS AND RELEVANCE These analyses identified several genomic regions of interest that require further exploration and validation. These data seem to demonstrate the utility of endophenotypes for resolving the genetic architecture of schizophrenia and characterizing the underlying biological dysfunctions. Understanding the molecular basis of these endophenotypes may help to identify novel treatment targets and pave the way for precision-based medicine in schizophrenia and related psychotic disorders.
Collapse
Affiliation(s)
| | - Laura C. Lazzeroni
- Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California,Sierra Pacific Mental Illness Research Education and Clinical Center, Department of Veterans Affairs (VA) Health Care System, Palo Alto, California
| | - Adam X. Maihofer
- Department of Psychiatry, University of California, San Diego, La Jolla
| | - Neal R. Swerdlow
- Department of Psychiatry, University of California, San Diego, La Jolla
| | | | - Robert Freedman
- Department of Psychiatry, University of Colorado Health Sciences Center, Denver
| | - Michael F. Green
- Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, California,Desert Pacific Mental Illness Research Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California
| | - Gregory A. Light
- Department of Psychiatry, University of California, San Diego, La Jolla,Desert Pacific Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, San Diego, California
| | | | | | - Allen D. Radant
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle,Northwest Geriatric Research Education and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington
| | - Larry J. Siever
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York,Research & Development, James J. Peters VA Medical Center, New York, New York
| | - Jeremy M. Silverman
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York,Research & Development, James J. Peters VA Medical Center, New York, New York
| | - William S. Stone
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts,Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Boston
| | - Catherine A. Sugar
- Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, California,Department of Biostatistics, UCLA School of Public Health
| | - Debby W. Tsuang
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle,Northwest Geriatric Research Education and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington
| | - Ming T. Tsuang
- Department of Psychiatry, University of California, San Diego, La Jolla
| | | | - Ruben C. Gur
- Department of Psychiatry, University of Pennsylvania, Philadelphia
| | - Raquel E. Gur
- Department of Psychiatry, University of Pennsylvania, Philadelphia
| | - David L. Braff
- Department of Psychiatry, University of California, San Diego, La Jolla
| |
Collapse
|
2
|
Keung YK, Knovich MA, Powell BL, Buss DH, Pettenati M. Constitutional pericentric inversion of chromosome 9 and acute leukemia. CANCER GENETICS AND CYTOGENETICS 2003; 145:82-5. [PMID: 12885469 DOI: 10.1016/s0165-4608(03)00055-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In view of the recent reports demonstrating delayed engraftment after autologous and allogeneic transplantation from donors with constitutional pericentric inversion of chromosome 9, [inv(9)], we conducted a retrospective study on six patients with acute leukemia and inv(9) to investigate if there is an impaired engraftment potential of the inv(9) hematopoietic stem cells. All but one of our patients had poor outcome. The hematopoietic recovery after induction chemotherapy was not prolonged. It is possible that the hematopoietic defects of inv(9) become more apparent after repeated courses of chemotherapy. Alternatively, the number of patients in our series may have been too small to detect a partial hematopoietic defect in patients with constitutional inv(9). Larger studies are required to confirm our findings.
Collapse
Affiliation(s)
- Yi-Kong Keung
- Department of Internal Medicine, Comprehensive Cancer Center of Wake Forest University Medical Center, Winston-Salem, NC 27157, USA.
| | | | | | | | | |
Collapse
|
3
|
Abstract
Linkage studies of mental illness have provided suggestive evidence of susceptibility loci over many broad chromosomal regions. Pinpointing causative gene mutations by conventional linkage strategies alone is problematic. The breakpoints of chromosomal abnormalities occurring in patients with mental illness may be more direct pointers to the relevant gene locus. Publications that describe patients where chromosomal abnormalities co-exist with mental illness are reviewed along with supporting evidence that this may amount to an association. Chromosomal abnormalities are considered to be of possible significance if (a) the abnormality is rare and there are independent reports of its coexistence with psychiatric illness, or (b) there is colocalisation of the abnormality with a region of suggestive linkage findings, or (c) there is an apparent cosegregation of the abnormality with psychiatric illness within the individual's family. Breakpoints have been described within many of the loci suggested by linkage studies and these findings support the hypothesis that shared susceptibility factors for schizophrenia and bipolar disorder may exist. If these abnormalities directly disrupt coding regions, then combining molecular genetic breakpoint cloning with bioinformatic sequence analysis may be a method of rapidly identifying candidate genes. Full karyotyping of individuals with psychotic illness especially where this coexists with mild learning disability, dysmorphism or a strong family history of mental disorder is encouraged.
Collapse
Affiliation(s)
- D J MacIntyre
- Department of Psychiatry, University of Edinburgh, Scotland, UK
| | | | | | | | | |
Collapse
|